Abstract
The validity of the Birmingham Vasculitis Activity Score (BVAS) as an index of disease activity and a predictor of the prognosis and outcome in patients with MPA has not yet been established in Japan. We conducted a retrospective study of the data of 73 patients with MPA who were followed up for at least 2 years. We divided the patients into two groups according to the BVAS, namely, the high-BVAS group (≥16) and the low-BVAS group (<16), and compared the clinical characteristics. In addition, the distribution of the BVAS items in the patients and the items contributing to the total score in MPA patients were analyzed. Remission was achieved in 85% of patients at 1 month. There were no significant differences in the serum CRP, creatinine (Cre), or MPO-ANCA between the high- and low-BVAS group; however, the survival time was significantly shorter (p = 0.048) and the mortality rate significantly higher in the high-BVAS group (p = 0.04). The items of the BVAS contributing to the total score were motor neuropathy, sensory neuropathy, pulmonary infiltrate, hematuria, proteinuria, Cre ≥5.6 mg/dL, hypertension, scleritis, rise in Cre by ≥30%, and myalgia. BVAS was found to be a useful tool for determining the disease activity and outcome in patients with MPA in Japan. The initial BVAS was also predictive of the mortality and survival time and can also be used as a prognostic tool; therefore, use of the tool may facilitate the selection of appropriate treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jennette JC, Falk RJ (1997) Small-vessel vasculitis. N Engl J Med 337:1512–1523
Jennette JC, Falk RJ (1998) Pathogenesis of the vascular and glomerular damage in ANCA-positive vasculitis. Nephrol Dial Transplant 13(Suppl 1):16–20
Watts RA, Scott DGI (2003) Overview of the inflammatory vasculitides. In: Hochberg MC, Silman A, Smolen JS, Weinblatt ME, Weissman MH (eds) Rheumatology, 3rd edn. Mosby, New York, pp 1583–1591
Jennette JC, Falk RJ, Andrassy K et al (1994) Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 37:187–192
Basu N, Watts R, Bajema I, Baslund B, Bley T, Boers M, Brogan P, Calabrese L, Cid MC, Cohen-Tervaert JW, Flores-Suarez LF, Fujimoto S, de Groot K, Guillevin L, Hatemi G, Hauser T, Jayne D, Jennette C, Kallenberg CG, Kobayashi S, Little MA, Mahr A, McLaren J, Merkel PA, Ozen S, Puechal X, Rasmussen N, Salama A, Salvarani C, Savage C, Scott DG, Segelmark M, Specks U, Sunderköetter C, Suzuki K, Tesar V, Wiik A, Yazici H, Luqmani R (2010) EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis 69:1744–1750
Guillevin L, Durand-Gasselin B, Cevallos R et al (1999) Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42:421–430
Fujimoto S, Uezono S, Hisanaga S, Fukudome K, Kobayashi S, Suzuki K et al (2006) Incidence of ANCA-associated primary renal vasculitis in Miyazaki prefecture: the first population-based, retrospective, epidemiologic survey in Japan. Clin J Am Soc Nephrol 1:1016–1022
Luqmani RA, Bacon PA, Moots RJ et al (1994) Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 87:671–678
Lane SE, Watts RA, Shepstone L, Scott DG (2005) Primary systemic vasculitis: clinical features and mortality. QJM 98:97–111
Flossmann O, Bacon P, de Groot K et al (2007) Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis 66:283–292
Mukhtyar C, Lee R, Brown D et al (2009) Modification and validation of the Birmingham vasculitis activity score (version 3). Ann Rheum Dis 68:1827–1832
Imai E, Matsuo S, Makino H et al (2008) Chronic Kidney Disease Japan Cohort (CKD-JAC) study: design and methods. Hypertens Res 31:1101–1107
Watts RA, Lane SE, Bentham G, Scott DG (2000) Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 43:414–419
Watts RA, Scott DG, Jayne DRW, Ito-Ihara T, Muso E, Fujimoto S et al (2008) Renal vasculitis in Japan and UK—are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant 23:3743–3745
Lane SE, Scott DG, Heaton A, Watts RA (2000) Primary renal vasculitis in Norfolk—increasing incidence or increasing recognition? Nephrol Dial Transplant 15:23–27
Green H, Paul M, Vidal L, Leibovici L (2007) Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 82:1052–1059
Koyama A, Yamagata K, Makini H, Arimura Y, Wada T, Nitta K, Nihei H, Muso E, Taguma Y, Shigematsu H, Sakai H, Tomino Y, Matsuo S, Japan RPGN Registry Group (2009) A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity. Clin Exp Nephrol 13:633–650
Gayraud M, Guillevin L, le Toumelin P, Cohen P, Lhote F, Casassus P, Jarrousse B, French Vasculitis Study Group (2001) Long-term follow-up of polyarteritis nodosa, microscopic polyangiitis, and Churg–Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 44:666–675
Guillevin L, Durand-Gasselin B, Cevallos R, Gaylaud M et al (1999) Microscopic polyangiitis. Arthritis Rheum 42:421–430
Acknowledgment
This study was supported by a grant from the Research Group on Progressive Glomerular Disease of the Ministry of Health, Labour, and Welfare of Japan. The authors thank Dr. Wako Yumura for advice of BVAS.
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Itabashi, M., Takei, T., Morito, T. et al. Estimation of BVAS in patients with microscopic polyangiitis in Japan. Clin Rheumatol 30, 1499–1505 (2011). https://doi.org/10.1007/s10067-011-1838-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-011-1838-7